Abstract
Secondary pulmonary hypertension (sPH) may develop as a result of few systemic diseases as endocrine diseases, HIV infection, collagen diseases, liver and hematological disorders. In this review we discuss the role of systemic diseases in inducing PH starting from a pathological classification.
Keywords: endothelial nitric oxide synthase, calcitonin, copd, endothelin-1, vasoconstrictor, growth hormone, hiv, myeloid metaplasia
Current Drug Targets - Inflammation & Allergy
Title: Pulmonary Hypertension and Systemic Diseases
Volume: 3 Issue: 4
Author(s): Rossella Paolini, Michela Armigliato and Sergio Zamboni
Affiliation:
Keywords: endothelial nitric oxide synthase, calcitonin, copd, endothelin-1, vasoconstrictor, growth hormone, hiv, myeloid metaplasia
Abstract: Secondary pulmonary hypertension (sPH) may develop as a result of few systemic diseases as endocrine diseases, HIV infection, collagen diseases, liver and hematological disorders. In this review we discuss the role of systemic diseases in inducing PH starting from a pathological classification.
Export Options
About this article
Cite this article as:
Paolini Rossella, Armigliato Michela and Zamboni Sergio, Pulmonary Hypertension and Systemic Diseases, Current Drug Targets - Inflammation & Allergy 2004; 3 (4) . https://dx.doi.org/10.2174/1568010042634613
DOI https://dx.doi.org/10.2174/1568010042634613 |
Print ISSN 1568-010X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-010X |
Related Articles
-
Hydrogen Sulfide: From Physiology to Pharmacology
Inflammation & Allergy - Drug Targets (Discontinued) Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery Molecular Cloning of a Novel PPEF-1 Gene Variant from a T-Cell Lymphoblastic Lymphoma Cell Line
Recent Patents on DNA & Gene Sequences The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?
Current Molecular Medicine Comparative Pharmacokinetics and Metabolism Studies in Lean and Diet- Induced Obese Mice: An Animal Efficacy Model for 11β -Hydroxysteroid Dehydrogenase Type 1 (11β -HSD1) Inhibitors
Drug Metabolism Letters Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets Military Risk Factors for Cognitive Decline, Dementia and Alzheimer’s Disease
Current Alzheimer Research Novel Agents Targeting Nitric Oxide
Current Vascular Pharmacology What Metabolic Syndrome Contributes to Brain Outcomes in African American & Caucasian Cohorts
Current Alzheimer Research The Renin Inhibitor Aliskiren as Novel Treatment for Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Meet Our Editor
Current Clinical Pharmacology Hypertension in 2017: Update in Treatment and Pharmaceutical Innovations
Current Pharmaceutical Design Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?
Current Molecular Medicine Different Omega-3 Formulations Yield to Diverse Clinical Response: A Case-Report
Current Drug Safety Editorial: Alteration of Redox Equilibrium, Inflammation and Progression of Disease
Current Medicinal Chemistry Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry Adverse Drug Reactions and Safety Considerations of NSAIDs: Clinical Analysis
Current Drug Safety Baroreflex Function: Determinants in Healthy Subjects and Disturbances in Diabetes, Obesity and Metabolic Syndrome
Current Diabetes Reviews Meet Our Editorial Board Member
Current Cardiology Reviews Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Current Vascular Pharmacology